BioCryst Announces Additional $2,5M NIAID Funding to Advance Development of BCX4430 to Treat Marburg Virus Disease
December 30, 2013 at 06:57 AM EST
BioCryst Pharmaceuticals (NASDAQ: BCRX ) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option to conduct the investigational new drug (IND)
